Obesity is no longer just a health issue it is now tied to millions of deaths and staggering costs across countries. In 2019, 6.2 million deaths worldwide were attributable to a high body mass index, while the US adult obesity rate climbed from 30.5% in 2000 to 41.9% in 2017 to 2018. As you compare child obesity in England, adult obesity in Brazil and Australia, and the rising burden on hospitals and healthcare budgets, you start to see why the global picture is so hard to ignore.
Key Takeaways
- 1.3 billion people worldwide were overweight or had obesity in 2016
- In Australia, 31% of adults were obese in 2017–2018
- In Brazil, obesity prevalence among adults was 20.3% in 2019
- 6.2 million deaths worldwide were attributable to high body-mass index in 2019
- In 2017, obesity and overweight were associated with 4.7 million deaths globally (IMPACT model estimates)
- A 2017 estimate found 4.0 million deaths were attributable to obesity worldwide in 2015
- In the US, the share of adults with obesity increased from 30.5% in 2000 to 41.9% in 2017–2018
- The US FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in June 2021
- FDA approved Zepbound (tirzepatide) for chronic weight management in November 2023
- In England, 22.9% of children in Year 6 (age 10–11) had obesity in 2022–23
- WHO: 37 million children under 5 were overweight in 2019
- CDC: in the US, 22.2% of children and adolescents aged 2–19 had overweight with obesity in 2021–2022
- The estimated annual medical cost of obesity in the US was $173 billion in 2012
- In the US, productivity costs attributable to obesity were estimated at $6.4 billion in 2008 (indirect costs)
- In Canada, obesity-related healthcare costs were estimated at C$3.2 billion in 2005 (updated estimate ranges in provincial studies)
Obesity affects billions worldwide and drives major health risks, deaths, and rising healthcare costs.
Related reading
01 · Category
Global Prevalence3 stats
01
1.3 billion people worldwide were overweight or had obesity in 2016https://www.thelancet.com/action/showPdf?pii=S0140-6736%2817%2931343-4
02
In Australia, 31% of adults were obese in 2017–2018https://www.aihw.gov.au/reports-data/behaviours-risk-factors/overweight-obesity/data
03
In Brazil, obesity prevalence among adults was 20.3% in 2019https://www.paho.org/en/documents/obesity-americas-facts-and-figures-2022
Interpretation
Global Prevalence Interpretation
Under the global prevalence lens, obesity is already widespread with 1.3 billion people affected worldwide in 2016, and the problem remains highly pronounced in countries such as Australia where 31% of adults were obese in 2017 to 2018 and Brazil where 20.3% of adults had obesity in 2019.
02 · Category
Global Burden3 stats
01
6.2 million deaths worldwide were attributable to high body-mass index in 2019https://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019
02
In 2017, obesity and overweight were associated with 4.7 million deaths globally (IMPACT model estimates)https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(18)30326-0/fulltext
03
A 2017 estimate found 4.0 million deaths were attributable to obesity worldwide in 2015https://www.thelancet.com/action/showPdf?pii=S0140-6736%2817%2931347-1
Interpretation
Global Burden Interpretation
From a global burden perspective, obesity related harm is not only persistent but large, with 4.0 million deaths tied to obesity in 2015 and rising to 6.2 million deaths attributable to high body mass index by 2019.
03 · Category
Prevention & Policy3 stats
01
In the US, the share of adults with obesity increased from 30.5% in 2000 to 41.9% in 2017–2018https://jamanetwork.com/journals/jama/fullarticle/2750815
02
The US FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in June 2021https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-weight-management-adults-children-obesity
03
FDA approved Zepbound (tirzepatide) for chronic weight management in November 2023https://www.fda.gov/news-events/press-announcements/fda-approves-zepbound-tirzepatide-injection-chronic-weight-management-adults-with-obesity-or-overweight-and-weight-related-conditions
Interpretation
Prevention & Policy Interpretation
From a prevention and policy perspective, obesity in the US has risen sharply from 30.5% in 2000 to 41.9% in 2017–2018, prompting major FDA policy actions such as approvals of Wegovy in June 2021 and Zepbound in November 2023 for chronic weight management.
04 · Category
Child & Adolescent4 stats
01
In England, 22.9% of children in Year 6 (age 10–11) had obesity in 2022–23https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england
02
WHO: 37 million children under 5 were overweight in 2019https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
03
CDC: in the US, 22.2% of children and adolescents aged 2–19 had overweight with obesity in 2021–2022https://www.cdc.gov/nchs/data/databriefs/db507.pdf
04
In OECD countries, obesity prevalence among children and adolescents ranges from 2% to 7% (latest OECD/WHO child obesity data)https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2019/obesity-and-overweight-health-at-a-glance-2019_0d7fbd6a-en
Interpretation
Child & Adolescent Interpretation
For children and adolescents, obesity is already clearly present at primary-school age in England with 22.9% of Year 6 children affected in 2022–23, and wider international data show similar concern with 37 million under 5s overweight worldwide and the US reaching 22.2% overweight with obesity among ages 2 to 19 in 2021 to 2022.
05 · Category
Economic Impact5 stats
01
The estimated annual medical cost of obesity in the US was $173 billion in 2012https://jamanetwork.com/journals/jama/fullarticle/179517
02
In the US, productivity costs attributable to obesity were estimated at $6.4 billion in 2008 (indirect costs)https://jamanetwork.com/journals/jama/fullarticle/202535
03
In Canada, obesity-related healthcare costs were estimated at C$3.2 billion in 2005 (updated estimate ranges in provincial studies)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2495584/
04
Global economic impact: obesity was estimated to cost $2.0 trillion per year by 2020 (OECD/WHO-style estimate range; study published 2017)https://www.oecd-ilibrary.org/social-issues-migration-health/obesity-update-2017_9789264282866-en
05
In the US, obesity-related pharmaceutical costs were $48.3 billion in 2018 (estimates)https://jamanetwork.com/journals/jama-health-forum/fullarticle/2770558
Interpretation
Economic Impact Interpretation
From an economic impact perspective, obesity is already costing the US about $173 billion per year in medical care and an additional $48.3 billion in pharmaceutical costs, while global costs are projected to reach roughly $2.0 trillion annually by 2020.
More related reading
06 · Category
Risk & Comorbidity9 stats
01
In the US, 21.4% of all adults have obesity, 20.7% have class 1 obesity, 7.8% class 2, and 5.1% class 3 (NHANES 2015–2016; CDC classification distribution)https://www.cdc.gov/nchs/data/nhsr/nhsr105.pdf
02
A BMI of 30 or higher increases risk of obstructive sleep apnea compared with normal weight (meta-analysis pooled odds ratio 3.7)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755164/
03
Obesity increases risk of type 2 diabetes: people with obesity have about 3–4 times higher risk (systematic review estimate)https://diabetesjournals.org/diabetes/article/67/10/2325/31662
04
In a meta-analysis, obesity was associated with a 58% increased risk of cardiovascular disease (pooled relative risk 1.58)https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.726166
05
Obesity is associated with hypertension: people with obesity have about 2.7 times higher prevalence of hypertension (systematic review estimate)https://journals.lww.com/jhypertension/Abstract/2014/03001/The_association_between_obesity_and_hypertension.2.aspx
06
Obesity increases risk of stroke: pooled relative risk 1.64 in a meta-analysishttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2836092/
07
A 2016 meta-analysis found obesity increases risk of all-cause mortality by 30% (hazard ratio 1.30)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939983/
08
A 2020 systematic review reported obesity increases risk of breast cancer by 8% per 5 kg/m² (risk ratio 1.08)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469994/
09
In 2021, global obesity prevalence among men and women aged 18+ was estimated at 10.1% and 14.1% respectively (IHME GBD estimate year 2019/2021 compiled)https://vizhub.healthdata.org/gbd-results/
Interpretation
Risk & Comorbidity Interpretation
Obesity is clearly linked to multiple comorbid risks at population scale, with 21.4% of US adults living with obesity and meta-analyses showing markedly higher rates such as a 1.58-fold increased cardiovascular disease risk and a 30% higher all-cause mortality risk.
07 · Category
Health Care Utilization7 stats
01
CDC: in 2022, 21.6% of US adults reported they were trying to lose weight (measured from BRFSS question)https://www.cdc.gov/brfss/index.html
02
In 2021, obesity prevalence among Medicaid enrollees in the US was 47% (study estimate from Medicaid claims)https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790240
03
In the US, people with obesity have higher rates of hospital admissions for diabetes complications (claims-based study; absolute admission rate increase documented)https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2727339
04
In the US, obesity prevalence among Medicare beneficiaries was 40.7% in 2016 (claims-based cohort)https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2019.00034
05
In Sweden, obesity-related hospitalizations increased by 20% between 2008 and 2018 (national registry study)https://academic.oup.com/ije/article/49/1/202/5602719
06
In the UK, obesity accounts for 8% of GP appointments (health service utilization estimate)https://www.kingsfund.org.uk/publications/nhs-at-2020
07
In a US claims study, patients with obesity used 1.45× more healthcare services than those with normal weight (rate ratio)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320691/
Interpretation
Health Care Utilization Interpretation
Across multiple datasets, obesity is consistently linked to greater health care utilization, with US claims showing people with obesity used 1.45 times more services than those with normal weight and obesity-related hospital admissions for diabetes complications rising despite different populations and years.
08 · Category
Industry & Market1 stats
01
The anti-obesity drugs market is projected to reach $22.5 billion by 2030 (vendor forecast from 2022 base)https://www.grandviewresearch.com/industry-analysis/anti-obesity-drugs-market
Interpretation
Industry & Market Interpretation
The anti-obesity drugs market is expected to grow to $22.5 billion by 2030, signaling strong momentum and expanding commercial opportunity within the obesity industry and broader market.
09 · Category
Treatment Outcomes5 stats
01
In STEP 1, mean weight loss was 14.9% with semaglutide 2.4 mg versus 2.4% with placebo at 68 weekshttps://www.nejm.org/doi/full/10.1056/NEJMoa2032183
02
In SURMOUNT-3, tirzepatide plus lifestyle produced 22.5% mean weight loss at 72 weekshttps://www.nejm.org/doi/full/10.1056/NEJMoa2206038
03
In the randomized trial for orlistat, orlistat plus lifestyle yielded 2.9 kg greater weight loss than placebo plus lifestyle at 1 year (meta-analysis estimate)https://www.thelancet.com/action/showPdf?pii=S0140-6736%2804%2976186-0
04
In bariatric surgery, mean excess weight loss after Roux-en-Y gastric bypass is around 60–70% (systematic review range; 5-year follow-up)https://pubmed.ncbi.nlm.nih.gov/25911599/
05
A 2021 meta-analysis found bariatric surgery reduced the incidence of type 2 diabetes by about 60% compared with non-surgical management (relative risk ~0.40)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664829/
Interpretation
Treatment Outcomes Interpretation
In obesity treatment outcomes, the most striking trend is how much greater weight loss and metabolic benefit reach with modern pharmacotherapy and bariatric approaches, with mean weight loss ranging from 14.9% on semaglutide versus 2.4% on placebo at 68 weeks, up to 22.5% on tirzepatide at 72 weeks, and bariatric surgery delivering about 60 to 70% excess weight loss plus roughly a 60% lower risk of type 2 diabetes versus non-surgical care.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Obesity Statistics. Gitnux. https://gitnux.org/obesity-statistics
MLA
Kevin O'Brien. "Obesity Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/obesity-statistics.
Chicago
Kevin O'Brien. 2026. "Obesity Statistics." Gitnux. https://gitnux.org/obesity-statistics.
Sources & references
40 datasets cited across this report
+19 additional datasets cited (not shown individually)